Study of INCB123667 in Subjects With Advanced Solid Tumors

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-exp

Trial Details

NCT ID
NCT05238922
Phase
PHASE1
Sponsor
Incyte Corporation
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • INCB0123667
  • Palbociclib
  • Bevacizumab
  • Olaparib
  • Paclitaxel
  • Ribociclib
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Los Angeles, California, United States|34.05223,-118.24368
  • Lone Tree, Colorado, United States|39.55171,-104.8863
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Adults aged 18 years or older at the time of the signing of the ICF.
  • Life expectancy greater than 12 weeks.
  • ECOG performance status score of 0 or 1.
  • Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available treatment to improve the d…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →